Answers are grounded in this paper and cite their sources.
Clinical trials with hematopoietic growth factors (granulocytemacrophage colony-stimulating factor [GM-CSF], granulocyte colony-stimulating factor [G-CSF], interleukin-3, or erythropoietin) have been performed on patients with myelodysplastic syndromes. Absolute neutrophil counts can be readily raised to within the normal range by treatment with GM-CSF or G-CSF. Increases in platelets and hemoglobin have been reported after treatment with interleukin-3 and erythropoietin, respectively. Cytogenetic and molecular genetic analyses have demonstrated that both normal and malignant precursor cells are stimulated by cytokine therapy.
No takes yet. Share an insight, caveat, or question.
PAQUETTE et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: